ABVC BIOPHARMA, INC.
About ABVC BIOPHARMA, INC.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $509.6K
- Net income
- -$7.9M
- Total assets
- $21.1M
- Market cap
- $34.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $7.2M
- Operating income
- -$7.2M
- Income tax
- $24.2K
- Net income
- -$8.4M
- EPS (basic)
- $-0.39
- EPS (diluted)
- $-0.39
Balance sheet
- Total assets
- $21.1M
- Current assets
- $2.5M
- Total liabilities
- $7.8M
- Current liabilities
- $6.2M
- Shareholders’ equity
- $13.3M
Cash flow
- Operating cash flow
- -$3.0M
- Investing cash flow
- -$1.2M
- Financing cash flow
- $4.6M
- Net cash flow
- $463.2K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $34.6M
- EPS (diluted)
- $-0.39
- Shares outstanding
- 23.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 9, 2004
At a glance
- Reported a net loss of $7.9M in FY2024.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ABVC BIOPHARMA, INC..
Write a review
News about ABVC BIOPHARMA, INC.
News & sentiment via Polygon.io
